IL206423A0 - Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects - Google Patents

Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects

Info

Publication number
IL206423A0
IL206423A0 IL206423A IL20642310A IL206423A0 IL 206423 A0 IL206423 A0 IL 206423A0 IL 206423 A IL206423 A IL 206423A IL 20642310 A IL20642310 A IL 20642310A IL 206423 A0 IL206423 A0 IL 206423A0
Authority
IL
Israel
Prior art keywords
reduce
side effects
botulinum toxin
clostridium botulinum
prevent side
Prior art date
Application number
IL206423A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Marx Matthias
Haunold Erich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa, Marx Matthias, Haunold Erich filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IL206423A0 publication Critical patent/IL206423A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
IL206423A 2007-12-21 2010-06-16 Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects IL206423A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US901007P 2007-12-21 2007-12-21
EP07024961A EP2072039A1 (en) 2007-12-21 2007-12-21 Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
PCT/EP2008/010782 WO2009080272A1 (en) 2007-12-21 2008-12-17 Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects

Publications (1)

Publication Number Publication Date
IL206423A0 true IL206423A0 (en) 2010-12-30

Family

ID=39401018

Family Applications (1)

Application Number Title Priority Date Filing Date
IL206423A IL206423A0 (en) 2007-12-21 2010-06-16 Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects

Country Status (13)

Country Link
US (1) US20100331259A1 (enExample)
EP (2) EP2072039A1 (enExample)
JP (1) JP2011506511A (enExample)
KR (1) KR20100107475A (enExample)
CN (1) CN101917960A (enExample)
AR (1) AR069806A1 (enExample)
AU (1) AU2008340713A1 (enExample)
CA (1) CA2709644A1 (enExample)
IL (1) IL206423A0 (enExample)
MX (1) MX2010006731A (enExample)
RU (1) RU2010130542A (enExample)
WO (1) WO2009080272A1 (enExample)
ZA (1) ZA201004393B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2018146550A1 (en) * 2017-02-10 2018-08-16 De Maio Domingos Mauricio Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US11090371B1 (en) * 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US11925677B2 (en) 2021-07-12 2024-03-12 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
AU2020365148B2 (en) 2019-10-18 2022-10-27 Penland Foundation Botulinum toxin for use in treatment
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US10960061B1 (en) * 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
KR102397708B1 (ko) * 2020-04-29 2022-05-16 한국화학연구원 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물
CN116096399A (zh) * 2020-06-03 2023-05-09 米奥托克斯有限责任公司 用于治疗偏头痛病症的区带性和靶向方法和用途
IL298399A (en) * 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
KR102724650B1 (ko) 2021-07-05 2024-11-01 주식회사 파마리서치바이오 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법
KR102724651B1 (ko) 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102551301B1 (ko) 2022-10-28 2023-07-03 주식회사 파마리서치바이오 보툴리눔 독소를 포함하는 안정한 액상 제제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
EP1602379A1 (en) * 1993-12-28 2005-12-07 Allergan, Inc. Botulinum toxin B for treating spastic muscle
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
CA2494241C (en) 2000-02-08 2011-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US6503653B2 (en) * 2001-02-23 2003-01-07 General Motors Corporation Stamped bipolar plate for PEM fuel cell stack
JP3830766B2 (ja) * 2001-03-09 2006-10-11 本田技研工業株式会社 燃料電池および燃料電池スタック
EP1491205A4 (en) * 2002-03-29 2007-04-25 Chemo Sero Therapeut Res Inst MEANS FOR THE TREATMENT OF HYPERMYOTONIA
US20040115222A1 (en) * 2002-09-06 2004-06-17 Michael Kane Method for reduction of wrinkles
JP2005089336A (ja) * 2003-09-12 2005-04-07 Tokyo Univ Of Agriculture Ｄ型ボツリヌス神経毒素の精製法
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
GB2426702A (en) * 2004-10-28 2006-12-06 Ipsen Ltd Pharmaceutical composition comprising botulinum neurotoxin
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
MX2010006731A (es) 2010-08-16
AR069806A1 (es) 2010-02-17
KR20100107475A (ko) 2010-10-05
CN101917960A (zh) 2010-12-15
CA2709644A1 (en) 2009-07-02
AU2008340713A1 (en) 2009-07-02
EP2231107A1 (en) 2010-09-29
EP2072039A1 (en) 2009-06-24
RU2010130542A (ru) 2012-01-27
ZA201004393B (en) 2011-08-31
WO2009080272A1 (en) 2009-07-02
US20100331259A1 (en) 2010-12-30
JP2011506511A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
IL206423A0 (en) Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects
EP2337778A4 (en) METHODS OF TREATING BOTULINUM TOXIN-RELATED DISEASE IN A SUBJECT
ZA200808491B (en) High frequency application of neurotoxic component of botulinum toxin
SG10201405582YA (en) Injectable Botulinum Toxin Formulations
IL214794A (en) A cell line derived from sima-sensitive toxins by botulinum toxin type a
GB2445951B (en) Hydro column
IL205280A0 (en) Methods of treating chronic neurogenic inflammation using modified clostridial toxins
EP2329347A4 (en) TIME-SEPARATED TOUCH ENTRY
IL244154A0 (en) Botulinum neurotoxin for use in the treatment of depression
ZA201208753B (en) Degradable clostridial toxins
HUE042159T2 (hu) Navigálás tevékenységek között egy számítógépen
IL215800A0 (en) Immunonanotherapeutics providing a th1-biased response
GB2500457B (en) Demoting partial tracks from a first cache to a second cache
ZA201107278B (en) Valve with biasing member
ZA201207139B (en) Idler mechanisms for hydraulic devices
PL1914770T3 (pl) Urządzenie do wykrywania pozycji względnej dwóch elementów o polepszonym połączeniu
SG10201500909UA (en) Functional fluid composition
TWM347480U (en) Non-contact type bearing sealing structure
GB2456680B (en) Hydro column
AU2008900648A0 (en) Downstream gasifier with multi-axis actuated bed interface to the reduction zone
GB0915701D0 (en) Endless track device for movable furniture
GB0805757D0 (en) Chess with mined squares
AU328331S (en) Finger sander
GB0710415D0 (en) Improvements relating to direct write and additive manufacturing processes
HUP0900405A2 (en) Running gear for sliding gates